In a report released today, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Coherus Biosciences (CHRS), with a price target of $25. The company’s shares opened today at $13.41.
According to TipRanks.com, Biasio is a 3-star analyst with an average return of 4.8% and a 65.1% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Mylan Inc, and Illumina.
Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $28.33, an 111.3% upside from current levels. In a report issued on March 1, Maxim Group also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
Based on Coherus Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $62.6 million. In comparison, last year the company had a GAAP net loss of $49.07 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar.
